Sign in or Register   Sign in or Register
  |  

Mouse Anti-B4GALNT1 Recombinant Antibody (5F9) (CBMAB-A0688-LY)

The product is antibody recognizes B4GALNT1. The antibody 5F9 immunoassay techniques such as: WB, ELISA.
See all B4GALNT1 antibodies

Summary

Host Animal
Mouse
Specificity
Human, Rat
Clone
5F9
Antibody Isotype
IgG2a, κ
Application
WB, ELISA

Basic Information

Immunogen
B4GALNT1 (NP_001469, 30 a.a. ~ 127 a.a) partial recombinant protein with GST tag.
Specificity
Human, Rat
Antibody Isotype
IgG2a, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, pH 7.4
Preservative
None
Concentration
Batch dependent
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Beta-1,4-N-Acetyl-Galactosaminyltransferase 1
Introduction
GM2 and GD2 gangliosides are sialic acid-containing glycosphingolipids. GalNAc-T is the enzyme involved in the biosynthesis of G(M2) and G(D2) glycosphingolipids. GalNAc-T catalyzes the transfer of GalNAc into G(M3) and G(D3) by a beta-1,4 linkage, resulting in the synthesis of G(M2) and G(D2), respectively. [provided by RefSeq]
Entrez Gene ID
Human2583
Rat64828
UniProt ID
HumanQ00973
RatQ10468
Alternative Names
GALGT; GALNACT
Function
Involved in the biosynthesis of gangliosides GM2, GD2, GT2 and GA2 from GM3, GD3, GT3 and GA3, respectively.
Biological Process
Carbohydrate metabolic process Source: ProtInc
Ganglioside biosynthetic process Source: UniProtKB
Glycosphingolipid metabolic process Source: Reactome
Lipid glycosylation Source: InterPro
Lipid storage Source: Ensembl
Spermatogenesis Source: Ensembl
Cellular Location
Golgi apparatus membrane
Involvement in disease
Spastic paraplegia 26, autosomal recessive (SPG26): A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG26 is a complicated form characterized by onset in the first 2 decades of life of gait abnormalities due to lower limb spasticity and muscle weakness. Some patients have upper limb involvement. Additional features include intellectual disability, peripheral neuropathy, dysarthria, cerebellar signs, extrapyramidal signs, and cortical atrophy. The disorder is slowly progressive.
Topology
Cytoplasmic: 1-7 aa
Helical: 8-25 aa
Lumenal: 26-533 aa
Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-B4GALNT1 Recombinant Antibody (5F9)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare